Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis

Journal of Obstetrics and Gynaecology Canada

Volumn 37, Issue 3, 2015, Pages 266-274

  van Schalkwyk, Julie ^a   Yudin, Mark H ^a   Allen, Victoria ^a   Bouchard, Celine ^a   Boucher, Marc ^a   Boucoiran, Isabelle ^a   Caddy, Sheila ^a   Castillo, Eliana ^a   Kennedy, V Logan ^a   Money, Deborah M ^a   Murphy, Kellie ^a   Ogilvie, Gina ^a   Paquet, Caroline ^a  

^a NONE   (Canada)

Author keywords

Bacterial vaginosis; Candidiasis; Treatment; Trichomonas vaginalis; Trichomoniasis; Vaginitis; Yeast

Indexed keywords

AMPHOTERICIN B; BORIC ACID; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE; KETOCONAZOLE; METRONIDAZOLE; MICONAZOLE; NYSTATIN; TERCONAZOLE; TINIDAZOLE;

ARTICLE; BACTEROIDES; CANDIDA ALBICANS; CANDIDA GLABRATA; CLINICAL FEATURE; CONGENITAL MALFORMATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; GARDNERELLA VAGINALIS; GRAM STAINING; HEADACHE; HUMAN; IMMUNOASSAY; INFECTION RISK; INSOMNIA; METALLIC TASTE; MOBILUNCUS; MYCOPLASMA; NAUSEA; PAPANICOLAOU TEST; PELVIC EXAMINATION; PREGNANCY OUTCOME; PREMATURE LABOR; PREVALENCE; PREVOTELLA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VAGINA CANDIDIASIS; VAGINITIS; VOMITING; XEROSTOMIA;

EID: 84973572637     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30316-9     Document Type: Article

References (76)

1. Sobel J.D. Management of patients with recurrent vulvovaginal candidiasis. Drugs 2003, 63:1059-1066.
2. Ohmit S., Sobel J., Schuman P., Duerr A., Mayer K., Rompalo A., et al. HIV Epidemiology Research Study (HERS) Group. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003, 188:118-127.
3. De Leon E., Jacober S.J., Sobel J.D., Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002, 2:1.
4. Odds F.C. Candidosis of the fenitalia. Candida candidosis: a review and bibliography 1988, 124. Bailliere Tindal, London. 2nd. F.C. Odds (Ed.).
5. Vermitsky J.P., Self M.J., Chadwick S.G., Trama J.P., Adelson M.E., Mordechai E., et al. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008, 46:1501-1503.
6. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
7. Public Health Agency of Canada Canadian guidelines on sexually transmitted infections-updated January 2010 2010, PHAC, Ottawa, Accessed on November 6, 2013, Available at:. http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/%20index-eng.php.
8. Nyirjesy P., Sobel J.D. Genital mycotic infections in patients with diabetes. Postgrad Med 2013, 125:33-46.
9. Watts D.H., Springer G., Minkoff H., Hillier S.L., Jacobsen L., Moxley M., et al. The occurrence of vaginal infections among HIV-infected and high-risk uninfected women: longitudinal findings of the Women's Interagency HIV Study. J Aquir Immune Defic Syndr 2006, 43:161-168.
10. Sobel J.D., Kapernick P.S., Zervos M., Reed B.D., Hooton T., Soper D., et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001, 185:363-369.
11. Pirotta M.V., Garland S.M. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 2006, 44:3213-3217.
12. Nurbai M., Grimshaw J.M., Watson M., Bond C.M., Mollison J., Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2007, 4:CD002845.
13. Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004, 351:876-883.
14. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
15. Guaschino S., De Seta F., Sartore A., Ricci G., De Santo D., Piccoli M., et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2001, 184:598-602.
16. Sobel J.D. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986, 315:1455-1458.
17. Roth A.C., Milsom I., Forssman L., Wahlen P. Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenopausal application of a 500 mg clotrimazole vaginal tablet. Genitourin Med 1990, 66:357-360.
18. Molgaard-Nielsen D., Pasternak B., Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Eng J Med 2013, 369:830-839.
19. Acs N., Banhidy F., Puho E., Czeizel A.E. Teratogenic effects of vaginal boric acid treatment during pregnancy. Int J Gynaecol Obstet 2006, 93:55-56.
20. Sutton M., Sternberg M., Koumans E.H., McQuillan G., Berman S., Markowitz L.E. The prevalence of Trichomonas vaginalis infection among reproductive age women in the United States, 2001-2004. Clin Infect Dis 2007, 45:1319-1326.
21. Gerbase A.C., Rowley J.T., Heymann D.H., Berkeley S.B.F., Piot P. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Dis 1998, 74(Suppl 1):S12-S16.
22. Peterson P. Trichomonas vaginalis vaginitis. A comparative study of treatment and incidence. Am J Obstet Gyn 1938, 35:1004-1009.
23. Paterson B.A., Tabrizi S.N., Garland S.M., Fairley C.K., Bowden F.J. The tampon test for trichomoniasis: a comparison between conventional methods and a polymerase chain reaction for Trichomonas vaginalis in women. Sex Transm Infect 1998, 74:136-139.
24. Cudmore S.L., Delgaty K.L., Hayward-McClelland S.F., Petrin D.P., Garber G.E. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev 2004, 17:783-793.
25. Kuberski T. Trichomonas vaginalis associated with nongonococcal urethritis and prostatitis. Sex Transm Dis 1980, 7:134-136.
26. Gupta P.K., Frost J.K. Cytopathology and histopathology of the female genital tract in Trichomonas vaginalis infection. Trichomonas parasitic in humans 1990, 274-290. Springer-Verlag, New York. B.M. Honigberg (Ed.).
27. Heine P., MacGregor J.A. Trichomonas vaginalis: a re-emerging pathogen. Clin Obstet Gynecol 1993, 36:137-1114.
28. Nye M.B., Schwebke J.R., Body B.A. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009, 200:188 e1. 188 e7.
29. Huppert J.S., Mortensen J.E., Reed J.L., Kahn J.A., Rich K.D., Miller W.C., et al. Rapid antigen testing compares favorably with transcription mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007, 45:194-198.
30. Lobo T.T., Feiho G., Carvalho S.E., Costa P.L., Chagas C., Xavier J., et al. A comparative evaluation of the Papanicolaou test for the diagnosis of trichomoniasis. Sex Transm Dis 2003, 30:694-699.
31. Andrea S.B., Chapin K.C. Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance paramenters and epidemiological implications. J Clin Microbiol 2011, 49:866-869.
32. Thin R.N., Symonds M.A.E., Booker R., Cook S., Langlet F. Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis. Br J Ven Dis 1979, 55:354-356.
33. Schmid G., Narcisi E., Mosure D., Secor W.E., Higgins J., Moreno H. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001, 46:545-549.
34. Forna F., Gulmezoglu A.M. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003, 2:CD000218.
35. Sorvillo F., Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 1998, 351:213-214.
36. Health Canada Guidance Document for Industry and Practitioners - Special Access Programme for Drugs 2013, Updated on December 20, 2013. Available at, Health Canada, Ottawa, Accessed on May 17, 2014. http://www.hc-sc.gc.ca/%20dhp-mps/access/drugs-drogues/index-eng.php.
37. Trichomoniasis 2013, Available at:, Centers for Disease Control, Atlanta (GA), Accessed on January 10, 2015. http://www.cdc.gov/std/trichomonas/default.htm.
38. Ling J., Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand 1981, 60:199-201.
39. Klebanoff M.A., Carey J.C., Hauth J.C., Hillier S.L., Nugent R.P., Thom E.A., et al. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001, 345:487-493.
40. Burtin P., Taddio A., Ariburnu O., Einarson T.R., Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995, 172(2 Pt 1):525-529.
41. Spiegel C.A., Amsel R., Eschenbach D., Schoenknecht F., Holmes K.K. Anaerobic bacteria in nonspecific vaginitis. N Engl J Med 1980, 303:601-607.
42. Eschenbach D.A. Bacterial vaginosis: emphasis on upper genital tract complications. Obstet Gynecol Clin North Am 1989, 16:593-610.
43. Hill G.B., Eschenbach D.A., Holmes K.K. Bacteriology of the vagina. Scand J Urol Nephrol Suppl 1985, 86:23-39.
44. Hillier S.L. Diagnostic microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993, 169:455-459.
45. Rein M.F., Holmes K.K. Non-specific vaginitis, vulvovaginal candidiasis, and trichomoniasis: clinical features, diagnosis and management. Curr Clin Top Infect Dis 1983, 4:281-315.
46. Fleury F.J. Adult vaginitis. Clin Obstet Gynecol 1987, 24:407-438.
47. Hillier S.L., Nugent R.P., Eschenbach D.A., Krohn M.A., Gibbs R.S., Martin D.H., et al. Vaginal Infections and Prematurity Study Group. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995, 333:1737-1742.
48. Gravett M.G., Hammel D., Eschenbach D.A., Holmes K.K. Preterm labor associated with subclinical amniotic fluid infection and with bacterial vaginosis. Obstet Gynecol 1986, 67:229-237.
49. Minkoff H., Brunebaum A.N., Schwartz R.H., Feldman J., Cummings M., Crombleholme W., et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984, 150:965-972.
50. Leitich H., Bodner-Adler B., Brunbauer M., Kaider A., Egarter C., Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003, 189:139-147.
51. Hillier S.L., Martius J., Krohn M.A., Kiviat N., Holmes K.K., Eschenbach D.A. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988, 319:972-978.
52. Watts D.H., Krohn M.A., Hillier S.L., Eschenbach D.A. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol 1990, 75:52-58.
53. Soper D.E., Bump R.C., Hunt W.G. Bacterial vaginosis and trichomonas vaginitis are risk factors for cuff cellulites after abdominal hysterectomy. Am J Obstet Gynecol 1990, 163:1016-1023.
54. Korn A.P., Bolan G., Padian N., Ohm-Smith M., Schacter J., Landers D.V. Plasma cell endometritis in women with symptomatic bacterial vaginosis. Obstet Gynecol 1995, 85:387-390.
55. Wiesenfeld H.C., Hillier S.L., Krohn M.A., Amortegui A.A., Heine R.P., Landers D.V., et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002, 100:456-463.
56. Goldenberg R., Klebanoff M., Nugent R., Krohn M., Hillier S., Andrews W., Infections Vaginal, Prematurity Study Group Bacterial colonization of the vagina during pregnancy in four ethnic groups. Am J Obstet Gynecol 1996, 174:1618-1621.
57. Jonsson M., Karlsson R., Rylander E., Gustavsson A., Wadell G. The associations between risk behaviour and reported history of sexually transmitted diseases, among young women: a population based study. Int J STD AIDS 1997, 8:501-505.
58. Hawes S.E., Hillier S.L., Benedetti J., Stevens C.E., Koutsky L.A., Wolner-Hanssen P., et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996, 174:1058-1063.
59. Brown J.M., Hess K.L., Brown S., Murphy C., Waldman A.L., Hezareh M. Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. Obstet Gynecol 2013, 121:773-780.
60. Verstraelen H., Verhelst R., Vaneechoutte M., Temmerman M. The epidemiology of bacterial vaginosis in relation to sexual behaviour. BMC Infect Dis 2010, 10:81.
61. Fethers K.A., Fairley C.K., Hocking J.S., Gurrin L.C., Bradshaw C.S. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis 2008, 47:1426-1435.
62. Amsel R., Totten P.A., Spiegel C.A., Chen K.C.S., Eschenbach D., Holmes K.K. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983, 74:14-22.
63. Nugent R.P., Krohn M.A., Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991, 29:297-301.
64. Lugo-Miro V.I., Green M., Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis. A meta-analysis. JAMA 1992, 268:92-95.
65. Hanson J.M., McGregor J.A., Hillier S.L., Eschenbach D.A., Kreutner A.K., Galask A.P., et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med 2000, 45:889-896.
66. Hillier S., Lipinski C., Briselden A.M., Eschenbach D.A. Efficacy of intravaginal 0.75% metronidazole gel for treatment of bacterial vaginosis. Obstet Gynecol 1993, 81:963-967.
67. Livengood C.H., Ferris D.G., Wiesenfeld H.C., Hillier S.L., Soper D.E., Nyirjesy P., et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis. A randomized controlled trial. Obstet Gynecol 2007, 110:302-309.
68. Schwebke J.R., Desmond R.A. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol 2011, 204:211.e1-211.e6.
69. Hay P. Recurrent bacterial vaginosis. Curr Infect Dis Rep 2000, 2:506-512.
70. Koumans E.H., Markowitz L.E. Hogan V; CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 2002, 35(Suppl 2):S152-S172.
71. Bradshaw C.S., Morton A.N., Hocking J., Garland S.M., Morris M.B., Moss L.M., et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006, 193:1478-1486.
72. Sobel J.D., Ferris D., Schwebke J., Nyirjesy P., Wiesenfeld H.C., Peipert J., et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006, 194:1283-1289.
73. Ya W., Reifer C., Miller L.E. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo- controlled study. Am J Obstet Gynecol 2010, 203:120.e1-120.e6.
74. Petersen E.E., Magnani P. Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomised, double blind, placebo-controlled trial. Eur J Ob Gyn Reprod Biol 2004, 117:70-75.
75. Yudin M.H. Money DM; Society of Obstetricians and Gynaecologists of Canada Infectious Diseases Committee. Screening and management of bacterial vaginosis in pregnancy. SOGC Clinical Practice Guideline, No. 211, August 2008. J Obstet Gynaecol Can 2008, 30:702-708.
76. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G., Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003, 169:207-208.